Cargando…

Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrell, Carl Randall, Jovicic, Biljana Popovska, Djonov, Valentin, Volarevic, Vladislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678745/
https://www.ncbi.nlm.nih.gov/pubmed/33274176
http://dx.doi.org/10.1155/2020/1939768
_version_ 1783612219608530944
author Harrell, Carl Randall
Jovicic, Biljana Popovska
Djonov, Valentin
Volarevic, Vladislav
author_facet Harrell, Carl Randall
Jovicic, Biljana Popovska
Djonov, Valentin
Volarevic, Vladislav
author_sort Harrell, Carl Randall
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the therapy of COVID-19-related ARDS.
format Online
Article
Text
id pubmed-7678745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-76787452020-12-02 Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome Harrell, Carl Randall Jovicic, Biljana Popovska Djonov, Valentin Volarevic, Vladislav Anal Cell Pathol (Amst) Research Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the development of a new coronavirus disease (COVID-19), is a highly transmittable virus which, in just ten months, infected more than 40 million people in 214 countries worldwide. After inhalation, aerosols containing SARS-CoV-2 penetrate to the depths of the lungs and cause severe pneumonia, alveolar injury, and life-threatening acute respiratory distress syndrome (ARDS). Since there are no specific drugs or vaccines available to cure or prevent COVID-19 infection and COVID-19-related ARDS, a new therapeutic agent which will support oxygen supply and, at the same time, efficiently alleviate SARS-CoV-2-induced lung inflammation is urgently needed. Due to their potent immuno- and angiomodulatory characteristics, mesenchymal stem cells (MSCs) may increase oxygen supply in the lungs and may efficiently alleviate ongoing lung inflammation, including SARS-CoV-2-induced ARDS. In this review article, we described molecular mechanisms that are responsible for MSC-based modulation of immune cells which play a pathogenic role in the development of SARS-CoV-2-induced ARDS and we provided a brief outline of already conducted and ongoing clinical studies that increase our understanding about the therapeutic potential of MSCs and their secretome in the therapy of COVID-19-related ARDS. Hindawi 2020-11-20 /pmc/articles/PMC7678745/ /pubmed/33274176 http://dx.doi.org/10.1155/2020/1939768 Text en Copyright © 2020 Carl Randall Harrell et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Harrell, Carl Randall
Jovicic, Biljana Popovska
Djonov, Valentin
Volarevic, Vladislav
Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
title Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
title_full Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
title_fullStr Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
title_full_unstemmed Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
title_short Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
title_sort therapeutic potential of mesenchymal stem cells and their secretome in the treatment of sars-cov-2-induced acute respiratory distress syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678745/
https://www.ncbi.nlm.nih.gov/pubmed/33274176
http://dx.doi.org/10.1155/2020/1939768
work_keys_str_mv AT harrellcarlrandall therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome
AT jovicicbiljanapopovska therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome
AT djonovvalentin therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome
AT volarevicvladislav therapeuticpotentialofmesenchymalstemcellsandtheirsecretomeinthetreatmentofsarscov2inducedacuterespiratorydistresssyndrome